LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

LLY

1,070.33

+0.82%↑

JNJ

206.53

-1.07%↓

ABBV

229.06

+2.46%↑

UNH

327.58

-0.05%↓

AZN

91.41

+0.61%↑

Strona główna・Stock List・Nektar Therapeutics

Nektar Therapeutics

Open

46.72 6.69

Buy Sell

Overview

Share price change

24h

Current

Min

44.01

Max

46.99

Key metrics
By Trading Economics
Income	6.1M -36M
Sales	615K 12M
EPS	-1.87
Profit margin	-301.289
Employees	61
EBITDA	6.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+128.66% upside

Market Stats
By TradingEconomics
Market Cap	-55M 1.1B
Previous open	40.03
Previous close	46.72

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

0.5949 / 0.7406 Support & Resistance

Nektar Therapeutics Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 gru 2025, 23:54 UTC

Hot Stocks

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 gru 2025, 23:51 UTC

Earnings

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 gru 2025, 23:39 UTC

Major Market Movers

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 gru 2025, 22:57 UTC

Acquisitions, Mergers, Takeovers

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 gru 2025, 21:40 UTC

Earnings

Nike Sales Tick Up, But China Weakness Persists

18 gru 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 gru 2025, 23:37 UTC

Market Talk

Earnings

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 gru 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 gru 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 gru 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 gru 2025, 23:00 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 gru 2025, 22:59 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 gru 2025, 22:58 UTC

Acquisitions, Mergers, Takeovers

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 gru 2025, 22:57 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 gru 2025, 22:56 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 gru 2025, 22:55 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 gru 2025, 21:59 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 gru 2025, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

18 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 gru 2025, 21:35 UTC

Earnings

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 gru 2025, 21:31 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Greater China Rev Down 17% >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q EPS 53c >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Apparel Rev $3.91B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Equipment Rev $550M >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q N Amer Rev $5.63B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Footwear Rev $7.66B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Greater China Rev $1.42B >NKE

Peer Comparison

Price change

Nektar Therapeutics Forecast

Price Target

By TipRanks

128.66% upside

12 Months Forecast

Average 103.88 USD 128.66%

High 135 USD

Low 30 USD

Based on 9 Wall Street analysts offering 12 month price targets forNektar Therapeutics - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Nektar Therapeutics - Dist in the past 3 months.

Technical Score

By Trading Central

0.5949 / 0.7406Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

Other stocks from the sector

LLY

Eli Lilly and Co.

1,070.33

↑ +0.82%

JNJ

Johnson and Johnson

206.53

↓-1.07%

ABBV

AbbVie Inc

229.06

↑ +2.46%

UNH

UnitedHealth Group Inc

327.58

↓-0.05%

AZN

AstraZeneca PLC ADR

91.41

↑ +0.61%

Nektar Therapeutics

Overview

Share price change

Key metrics

Recommendations

Market Stats

Technical Score

Nektar Therapeutics Chart

Related News

Peer Comparison

Nektar Therapeutics Forecast

Price Target

Rating Consensus

Technical Score

Financials

Other stocks from the sector